It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Objective: To explore the method and clinical effect of applying Yiqi Tongnao Decoction in the treatment of patients with acute cerebral infarction of Qi deficiency and blood stasis. Methods: To carry out research work in our hospital, a total of 70 patients with acute cerebral infarction of Qi deficiency and blood stasis who were treated in our hospital from March 2018 to March 2019 were randomly divided into two groups, one of which was given Western Medicine as the control group, and the other group was given Yiqi Tongnao Decoction combined with Western medicine, as the research group, the treatment status of the two groups of patients was compared and observed. Results: When comparing, the research group with skewed mouth and eyes, white greasy tongue coating, shortness of breath and fatigue, and pulse fineness scores were lower than those of the control group. The data difference between the groups was shown as P <0.05. The difference between the research group and the control group is quite large. Before treatment, the NIHSS score of the two groups of patients did not change significantly, P> 0.50. After the treatment intervention, the score of the research group was (5.10 ± 1.24), which was lower than that of the control group, and the difference between the groups was P <0.05. Before receiving treatment, there was no significant difference in blood lipid levels between the two groups of patients, P> 0.05. After treatment, the blood lipid level of the two groups of patients both changed, but in contrast, the degree of change in the research group was significantly greater than that of the control group, P <0.05, in general, the treatment effect of the research group was better. Conclusion: In the treatment of patients with acute cerebral infarction of qi deficiency and blood stasis, Yiqi Tongnao Decoction has significant effects, which can effectively improve the patients' adverse symptoms and has positive significance for clinical development.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer